A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

This study is currently recruiting participants.

Verified October 2012 by Eisai Inc.

Study NCT01432886 Information provided by Eisai Inc.

First Received on September 12, 2011. Last Updated on October 15, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Breast Cancer

Additional conditions recognized in this trial

Breast Neoplasms

More general conditions related to this trial

Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

Interventions listed in this trial

E7389

Additional drug interventions recognized in this trial

Mitogens
Trastuzumab

More general drug interventions related to this trial

Sponsors listed in this trial

Eisai Co., Ltd.